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Summary
After conducting appropriate animal 
tests to ascertain safe levels, human 
subjects were exposed to concentrations 
of from 1.25% to 16.9% V/V of FE 1301. 
Assessment of judgement, alertness and 
neuromuscular skill indicated minimal 
but discernible effects at the lowest 
concentration in some individuals. At 
10% V/V all subjects were effected. 
Stage I anesthesia occurred at 15% and 
Stage II would probably have occurred at 
20%. A marked cardiac arrhythmia re­ 
sulted in one subject exposed to 14%. 
There was complete recovery in all sub­ 
jects within 20 minutes after exposure. 
No liver dysfunction occurred. The crit­ 
ical level for effective fire control is 
near 6%. This level would be acceptable 
on clinical toxicologic criteria.
Introduction
This study of the pharmacology and 
toxicology of the fluorocarbon fire ex­ 
tinguishing agent, Freon © FE 1301, has 
special reference to possible myocardial 
sensitizing properties of the compound, 
and effects on the central nervous sys­ 
tem.
It was conducted for the purpose of 
evaluating the medical aspects of toxi- 
cological hazards inherent in the release 
of FE 1301 into closed spaces such as 
aircraft cockpits or cabins. Although no 
adverse effects have been encountered in 
the use of portable extinguishers con­ 
taining FE 1301 , it is known that some 
halogenated hydrocarbons, as well as 
simple hydrocarbons, can cause abnormal­ 
ities in cardiac rhythm when inhaled by 
persons with high blood levels of adren­ 
alin.
The investigation was done in two 
parts. The first part involved exposure 
of dogs to various levels of FE 1301 
under fright-producing situations in 
order to ascertain whether endogenously 
released epinephrine would cause myocar­ 
dial arrhythmias. The second part was
concerned with exposure of human subjects 
to varying concentrations with measuremert 
of mental alertness and acuity and moni­ 
toring of the electrical activity of the 
myocardium. Extensive animal studies had 
been conducted by the toxicology group 
at the du Pont Company, the Hazelton Lab­ 
oratories and Dr. Back, Wright-Patterson 
Air Force Base, Dayton, Ohio.
Stoppes of the Haskell Laboratories 
exposed three volunteers to concentra­ 
tions up to 10% for 3-1/2 minutes. No 
other studies had previously been con­ 
ducted on man. The intent of this study 
was to obtain data which might help de­ 
fine those levels which could be consid­ 
ered as safe for passengers and operative 
personnel in those situations where there 
might be need for exposure to FE 1301.
Experimental Approach
Material
The test material FE 1301 is identi­ 
fied chemically as bromotrifluoromethane 
(chemical symbol: CBrF3). The material 
was furnished through the courtesy of 
Freon Products Division of E. I. du Pont 
de Nemours and Company. The material was 
described as typical of commercial pro­ 
duction and free from impurities. Fluoro­ 
carbon 22B1 (CHBrF2) and fluorocarbon 
12B2 (CBr2F2) were stated to be present 
at concentrations of less than 1 ppm 
though specifications on the product 
would allow up to 50 ppm of either com­ 
pound. Free halogen or acids were stated 
to be absent.
Exposure Facilities
All exposures took place in a cubi­ 
cle exposure chamber of 8064 liter capa­ 
city. The chamber was lighted and equip­ 
ped with circulating fans. All exposures 
were made in a static environment. Ex­ 
posure in man lasted up to 25 minutes.
Determination of FE 1301
An appropriate method was developed 
for the determination of air concentra­ 
tions of FE 1301 utilizing an Aerograph 
600 gas-liquid chromatograph. For this 
purpose we used a hydrogen flame ioniza- 
tion detector and a stainless steel tube 
column, i.d. 4 mm. and 15 cm. in length, 
packed with 80-100 mesh Polapak "A". A 
volume of one ml. of gas under these con­ 
ditions gave a full scale deflection at 
16 volumes percent with X4 attenuation.
Production of Desired Concentration
FE 1301 gas was allowed to flow from 
the cylinder at a metered rate into the 
chamber to give the desired nominal con­ 
centrations. The air and FE 1301 input 
were adjusted to achieve the desired con­ 
centration which was then monitored and 
maintained at this level (or within 1.4% 
of this level) for the remainder of the 
exposure.
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Exposure of Human Subjects 
Test Subjects
Fifteen test subjects were used in 
assessment of the effects of FE 1301 on 
behavior and 10 on myocardial irritabil­ 
ity. They were drawn from the population 
of research personnel, medical and dental 
students from the professional schools at 
the University of California at San Fran­ 
cisco. The nature of the test and the 
risks involved were explained to each sub­ 
ject emphasizing that the clinical pharm­ 
acology of the substance had not been 
fully ascertained and that this was part 
of the purpose of the experiment.
General Procedure
Subsequent to acceptance into the 
program we questioned them concerning 
their previous experience with anesthe­ 
tics, allergies and sensitivities, and 
current drug ingestion. A physical ex­ 
amination was performed and their mood 
and affect appraised. Where high concen­ 
trations were to be used an electrocardi­ 
ogram was taken. Prior to exposure all 
subjects were trained to acceptable Ieve3s 
of performance on tests measuring mental 
alertness and neuromuscular coordination. 
The FE 1301 was administered to four sub­ 
jects at 1.25%, six subjects at 2.5%, 
four subjects at 5% and six at 10%. While 
in the chamber, subjects made observations 
as to sensory stimulation and carried out 
tests for mental alertness and neuromus­ 
cular coordination. All exposures were 
for 22 minutes or until the subjects com­ 
pleted the schedule given below:
Time 
(Minutes) Test
0 Record Sensory Experience
1 Record Sensory Experience
2 Record Sensory Experience




10 Record Sensory Experience
11 Perform Pursuit Rotor
15 Record Sensory Experience
16 Perform Simple Reaction
20 Record Sensory Experience
21 Perform Maze
Leave chamber and narrate description
of exposure experience.
Experiments Monitoring Vital Signs
Ten subjects were administered FE 
1301 in concentrations of 5-16% by mask. 
During this time pulse, respirations, 
blood pressure and electrical activity -of 
the heart were monitored. Carbon dioxide 
at 5-10% was administered intermittently 
to six subjects.
Control of Bias
The experiment was carried out on a 
single blind basis but without placebo 
control, subjects being unaware of the 
concentrations that were being administered.
Final interpretation of the electrocardi­ 
ograms was made without the reader's 
knowledge of the concentration to which 
the subjects had been exposed.
Results 
Characteristics of the Subjects
The age span was 22 to 33 years of 
age. Only one of the subjects was re­ 
ceiving chronic medication. Seven had a 
past history of allergies and sensitivi­ 
ties. Two of these were currently clini­ 
cally active. One subject had a systolic 
murmur accentuated by exercise and had a 
history of a congenital heart problem.
Levels of Exposure
The concentrations determined by GLC 
were close to nominal concentrations in 
all runs.
Unusual Events
The experiment proceded satisfactor­ 
ily according to experimental design and 
it was not necessary to significantly al­ 
ter any of the procedures during the 
course of the investigation. No subject 
asked to terminate his chamber exposure; 
however, three subjects breathing mask- 
concentrations of 12% or greater had a 
feeling of impending unconsciousness. 
Subject 5 developed an unusual myocardial 
activity and dissociation of the pace 
maker after reaching a level of 16.1%, so 
his exposure was discontinued. Return to 
normal rhythm occurred within 3 minutes. 
It was not necessary to use any resusci- 
tative devices at any time. All subjects 
recovered from their central nervous sys­ 
tem depression within 20 minutes after 
exposure. Two subjects reported headache 
during or following exposure; one of these 
persisted for 12 hours.
Mental Alertness and Neuromuscular Coor­ 
dination
There was a deterioration in perfor­ 
mance in one or more tests at all of the 
four levels of exposure. Test in which 
the fingers were brought into proximation 
was the most sensitive and showed de­ 
creased performance at the lowest level 
tested. The maze test was second in sen­ 
sitivity and decreased performance and 
was correlated with increasing FE 1301 
concentration. The Romberg test was the 
least sensitive showing no effect until 
the 10% level was reached when 3 of 6 sub­ 
jects failed the test. Scores obtained 
in the rotor and simple reaction time 
tests did not correlate with concentration; 
in a number of instances in both tests 
there was improvement following exposure. 
At the 1.25% concentration there was con­ 
vincing evidence of decrement in the 
finger-to-finger test and decrement in 4 
of the 8 maze tests. At 2.5% finger-to- 
finger test again was more poorly per­ 
formed by all subjects and there was a de­ 
crease in coordination as measured by the 
rotor test. There was no significant 
change at the 5% level of exposure. At
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the 10% level there was a marked decre­ 
ment in performance of the maze test as 
well as the finger-to-finger coordination 
test and failure of Romberg test. Im­ 
provement in skill test scores when the 
is exposed to central nervous system de­ 
pressants is not the expected event but 
is sometimes observed in tests of the 
type used here. Two explanations are 1) 
an increase in the learning curve which 
continues during the testing session and 
2) relaxation of tensions with a decrease 
in tendency to over-correct. At the 10% 
level there were 6 tests in which there 
were improvements , 7 in which there was 
no change and 23 in which there was a de­ 
crement performance.
Descriptive Words
The results of this test indicated 
a clear pattern of change in self apprai­ 
sal of mood and mental clarity. There 
was a decrease in words with positive 
values such as alert, careful, clear­ 
headed, forceful, industrious, resource­ 
ful and increase in words with negative 
values such as detached, drowsy, dull, 
elated, groggy, irritable, lackadaisical, 
lightheaded, sluggish and talkative. 
Fifty percent of the subjects at the low­ 
est level and all of the subjects at the 
highest.level indicated a feeling of 
lightheadedness . This generally was 
noted after 3 to 5 minutes of exposure.
Sensory Appraisal
The majority of subjects did not ex­ 
perience eye irritation, nose irritation 
or pulmonary discomfort during most of 
the period of testing. No eye irritation 
was noted at the two lower levels. Two 
subjects noted a slight irritation at 
both the 5 and 10% levels while one re­ 
sponded with moderate irritation at the 
10% level. Only slight nasal irritation 
was noted by any subjects at the three 
lower levels; however, one subject classi­ 
fied nasal irritation at the 10% level as 
severe. This was identified as a bromine- 
like odor. Pulmonary discomfort descri­ 
bed as either a feeling of coolness in 
the respiratory tract or nasal stuffiness 
was rated as no more than slight at any 
level. Olefactory recognition was rated 
as moderate in intensity by one or more 
subjects at all levels. Generally there 
was a decreased olefactory cognition with 
time. Lightheadedness just detected at 
the lower levels of exposure increased to 
a moderate disturbance in alertness and 
mental acuity in one of the four subjects 
at the 5% level, while three of the six 
subjects at the 10% level described 
marked sensation of giddiness and loss of 
normal alertness. Judging from all fac­ 
tors, it can be concluded that at concen­ 
trations at 10% a state of inebriation 
was beginning to appear.
The narrative descriptions defined 
varying degrees of central nervous system 
depression with paresthesias, alteration 
in auditory perception, euphoria, and 
silliness occurring at levels of 5%. 
There was numbness about the lips and
beginning inebriation at the 10% level. 
A feeling of pending unconsciousness was 
related by three subjects at concentra­ 
tions of 14.4 to 16.9%. Only one subject 
who reached 15% did not feel markedly 
confused.
Electrocardiographic Changes
There were no significant and unex­ 
pected findings at the baseline electro­ 
cardiograms. No changes occurred in 
seven of the EKG's during exposure even 
when concentrations of as high as 16.9% 
were reached. One subject had lowering 
of the T-wave 5 minutes after exposure to 
8.2% of FE 1301 and 26 minutes later at a 
concentration of 12.1% when carbon dioxide 
had been added to the inhalant mixture. 
A second subject had flattening of the T- 
waves after 10 minutes of exposure at 
12.5% FE 1301 >and increased sinus arrhy­ 
thmia at a later time. The most marked 
changes were noted in a 24-year old, 165 
pound, Caucasian male of athletic build, 
hypertonic in mood and affect. Five min­ 
utes after exposure to 12.8% of FE 1301, 
he developed a flattening of the T-wave. 
This was followed in two minutes by pre­ 
mature ventricular contractions and one 
minute later when the concentration had 
reached 14% by auricular-ventricular dis­ 
sociation. Rhythm was restored two min­ 
utes after cessation of the exposure.
Discussion
Study of the toxicity and biology of 
the fluorocarbons indicates that FE 1301 
is one of the least toxic members of this 
class. The majority of overt pharmaco- 
logic signs refer to the central nervous 
system, the principal effect being narco­ 
sis, and anesthesia. However, there have 
been reported tremors and convulsive re­ 
actions in dogs exposed at high concen­ 
trations. Based on our experiments the 
only effect on the central nervous system 
of man which would be expected at concen­ 
trations short of those producing uncon­ 
sciousness would be decreased awareness 
and alertness and slight confusion. A 
large number of halogenated hydrocarbons 
may cause cardiac sensitization to epine- 
phrine; according to the evidence devel­ 
oped in animals and now in man FE 1301 
would have to be classified among these 
compounds. The occurrence of cardiac ar­ 
rhythmias is dose related, based on exten­ 
sive experience with the anesthetics cy­ 
clopropane and chloroform. Arrhythmias 
produced by these compounds and presumably 
FE 1301 include a wandering pacemaker, 
atrial extrasystoles, atrial fibrillations, 
sporadic ventricular extrasystoles, mild 
focal and multifocal ventricular tachy­ 
cardias and bigeminal rhythm. Given a 
large enough series of exposed persons at 
high enough concentrations and under se­ 
vere conditions of epinephrine release, 
the probability exists that FE 1301 could 
produce myocardial sensitization and sig­ 
nificant cardiac arrhythmia. The question 
therefore evolves about the relative de­ 
gree of risk. The number of subjects in 
our study in whom the electrical activity 
was monitored is small, however we observed
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no arrhythmias at concentrations below 
10%. We did not establish an anesthetic 
level for our human subjects. However, 
the majority approached Stage I (anal­ 
gesia) at concentrations of about 14%. 
The stage of delerium would probably have 
been achieved when an additional 2-3% was 
present. Loss of consciousness would oc­ 
cur, in our opinion, in most people at 
about 20 volumes %. At concentrations of 
10% of FE 1301 or greater all subjects ex­ 
perienced some degree of confusion, mis­ 
interpretation of the surroundings or un­ 
steadiness and giddiness. Clearly, one 
would have difficulty in sustaining com­ 
plex operations at such concentrations. 
Tasks requiring precise timing and high 
degree of coordination would undoubtedly 
deteriorate. At the 5% level while ef­ 
fected to some degree by lightheadedness 
and change in mood, skilled tasks could 
be performed and even balance and locomo­ 
tion were unimpaired. In the sitting po­ 
sition the sensation was not at all un­ 
pleasant nor was there any distress. In­ 
halation of the FE 1301 produces a sen­ 
sation which in the inexperienced is 
slightly disturbing; however, those who 
previously had received anesthetics or 
consumed moderate quantities of alcoholic 
beverages were familiar with the sensa­ 
tion produced and were not disturbed by 
the exposure at concentrations of 10% or 
below.
There is no reason, based on our 
study, to believe that passengers would 
have any significant degree of confusion 
or be incapable of leaving their seats 
were rapid evacuation of the cabin area 
necessary at a FE 1301 level of 6%.
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